Inhibikase Therapeutics earnings release, August 11, 2026
Inhibikase Therapeutics Announces Second Quarter 2026
Financial Results and Highlights Recent Activity
WILMINGTON, Del., August 11, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or
“Company”), a clinical-stage pharmaceutical company developing
IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.
“During our second quarter and in recent weeks we continued to advance our Phase 3
IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries,” said Mark Iwicki, Chief Executive
Officer of Inhibikase. “Also, during the quarter, favorable results of pre-clinical and Phase 1 studies of
IKT-001 were presented at the
American Thoracic
Society International Conference, with data demonstrating improvements in pulmonary vascular and hemodynamic markers of PAH and lower potential for GI toxicity compared to imatinib mesylate. Together with the recent grant of Orphan Drug
Designation from the U.S. FDA and the $50 million proceeds from the sale of shares to RA Capital, Inhibikase is well-positioned to advance
IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population.”
Recent Developments¹
Presentations
Financial Results
Cash Position:
As of
June 30, 2026, cash, cash equivalents and marketable securities were $159.0 million. Subsequent to the close of the quarter the Company announced that it had sold 25,000,000 shares of the Company’s common stock to RA Capital
Management through its ATM facility for gross proceeds of $50 million. The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in
Part B of the ongoing global Phase 3
IMPROVE-PAH clinical study, assuming the full and timely exercise of the outstanding Series A and B Warrants.
As of June 30, 2026, there were 132.0 million shares of common stock and 42.5 million pre-funded warrants outstanding.
Net Loss:
Net loss for the quarter ended June 30, 2026, was $19.6 million, or $0.11 per share, compared to a net loss of $9.9 million, or $0.11 per share in the quarter ended June 30, 2025. Net loss for the six months ended June 30, 2026, was $36.0 million, or $0.21 per share, compared to a net loss of $23.6 million, or $0.26 per share, for the six months ended June 30, 2025.
R&D Expenses:
Research and development expenses were $13.4 million for the quarter ended June 30, 2026, compared to $5.3 million for the quarter ended June 30, 2025. Research and development expenses were $24.2 million for the six months ended June 30, 2026, compared to $15.8 million for the six months ended June 30, 2025.
SG&A Expenses:
Selling, general and administrative expenses for the quarter ended June 30, 2026 were
$7.7 million, compared to $5.9 million for the quarter ended June 30, 2025. Selling, general and administrative expenses for the six months ended June 30, 2026 were $15.0 million, compared to $11.2 million for the six months ended June 30, 2025, which included $1.0 million of severance expenses for prior senior executives of the Company.²
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as
“c-Kit,” has been implicated. Our lead product candidate is
IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named
IMPROVE-PAH
(
I
KT-001 for
M easuring
P ulmonary Vascular
R esistance and
O utcome
V ariables in a Phase 3
E valuation of
PAH), is actively enrolling patients.
Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases,
SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under
Regulation FD.
Financial statements
Income Statement
Three Months Ended June 30, — (Unaudited)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Costs and expenses: | Research and development | 13,393,464 | 5,270,967 | 24,232,614 | 15,784,546 |
| Costs and expenses: | Selling, general and administrative | 7,657,531 | 5,919,731 | 15,033,654 | 11,169,022 |
| Costs and expenses: | Change in fair value contingent consideration | -358,420 | -373,354 | -1,523,284 | |
| Costs and expenses: | Total costs and expenses | 21,050,995 | 10,832,278 | 38,892,914 | 25,430,284 |
| Costs and expenses: | Loss from operations | -21,050,995 | -10,832,278 | -38,892,914 | -25,430,284 |
| Costs and expenses: | Other income | 1,459,764 | 916,755 | 2,920,843 | 1,836,026 |
| Costs and expenses: | Net loss | -19,591,231 | -9,915,523 | -35,972,071 | -23,594,258 |
| Costs and expenses: | Other comprehensive income (loss), net of tax Unrealized gain (loss) on marketable securities | -46,461 | -1,977 | -94,556 | 34,304 |
| Costs and expenses: | Comprehensive loss | -19,637,692 | -9,917,500 | -36,066,627 | -23,559,954 |
| Costs and expenses: | Net loss per share – basic and diluted | -0.11 | -0.11 | -0.21 | -0.26 |
| Costs and expenses: | Weighted-average number of shares – basic and diluted | 174,571,543 | 90,009,625 | 173,445,493 | 89,774,703 |
Balance Sheet
June 30, 2026 — (Unaudited)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 31,206,707 | 139,220,208 |
| Current assets: | Marketable securities | 127,812,140 | 39,543,820 |
| Current assets: | Prepaid research and development | 2,346,641 | 1,001,993 |
| Current assets: | Prepaid expenses and other current assets | 933,938 | 343,374 |
| Current assets: | Deferred offering costs | 44,489 | |
| Current assets: | Total current assets | 162,343,915 | 180,109,395 |
| Current assets: | Prepaid research and development, noncurrent | 1,000,000 | 1,000,000 |
| Current assets: | Other assets | 244,697 | 95,121 |
| Current assets: | Total assets | 163,588,612 | 181,204,516 |
| Current liabilities: | Accounts payable | 991,720 | 1,158,054 |
| Current liabilities: | Accrued expenses and other current liabilities | 9,268,306 | 4,081,282 |
| Current liabilities: | Contingent consideration liability | 3,061,501 | |
| Current liabilities: | Total current liabilities | 10,260,026 | 8,300,837 |
| Current liabilities: | Total liabilities | 10,260,026 | 8,300,837 |
| Stockholders’ equity: | Common stock, $0.001 par value; 500,000,000 shares authorized; 132,032,636 and 131,691,237 shares issued and outstanding (including 0 and 4,149,252 contingently issuable shares - see Note 10) at June 30, 2026 and December 31, 2025, respectively | 132,032 | 131,691 |
| Stockholders’ equity: | Additional paid-in capital | 331,921,179 | 315,429,986 |
| Stockholders’ equity: | Accumulated other comprehensive income (loss) | -72,754 | 21,802 |
| Stockholders’ equity: | Accumulated deficit | -178,651,871 | -142,679,800 |
| Stockholders’ equity: | Total stockholders’ equity | 153,328,586 | 172,903,679 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 163,588,612 | 181,204,516 |
Cash Flow
Six months ended June 30, — (Unaudited)
| Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|
| Cash flows from operating activities | Net loss | -35,972,071 | -23,594,258 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation | 36,812 | |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation expense | 10,905,776 | 6,250,938 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Write-off of in-process research and development | 7,357,294 | |
| Adjustments to reconcile net loss to net cash used in operating activities: | Change in fair value contingent consideration | -373,354 | -1,523,284 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Non-cash accretion on marketable securities | -1,969,587 | |
| Changes in operating assets and liabilities: | Operating lease right-of-use assets | 66,519 | |
| Changes in operating assets and liabilities: | Prepaid expenses and other current assets | -590,564 | 7,526 |
| Changes in operating assets and liabilities: | Prepaid research and development | -1,344,648 | -57,547 |
| Changes in operating assets and liabilities: | Other assets | -149,576 | |
| Changes in operating assets and liabilities: | Accounts payable | -196,334 | 1,592,656 |
| Changes in operating assets and liabilities: | Operating lease liabilities | -72,573 | |
| Changes in operating assets and liabilities: | Accrued expenses and other current liabilities | 5,187,024 | 258,156 |
| Changes in operating assets and liabilities: | Net cash used in operating activities | -24,503,334 | -9,677,761 |
| Cash flows from investing activities | Purchases of equipment and improvements | -13,399 | |
| Cash flows from investing activities | Purchases of investments - marketable securities | -145,618,289 | |
| Cash flows from investing activities | Maturities of investments - marketable securities | 59,225,000 | 31,350,103 |
| Cash flows from investing activities | Acquired in-process research and development | -438,624 | |
| Cash flows from investing activities | Net cash provided by (used in) investing activities | -86,393,289 | 30,898,080 |
| Cash flows from financing activities | Deferred offering costs | -14,489 | |
| Cash flows from financing activities | Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs | 2,897,611 | 150 |
| Cash flows from financing activities | Issuance of common stock from exercise of options | 31,621 | |
| Cash flows from financing activities | Net cash provided by financing activities | 2,883,122 | 31,771 |
| Cash flows from financing activities | Net increase (decrease) in cash and cash equivalents | -108,013,501 | 21,252,090 |
| Cash flows from financing activities | Cash and cash equivalents at beginning of period | 139,220,208 | 56,490,579 |
Full release
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,”
“will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential of
IKT-001,... (truncated)the advancement of the Company’s global pivotal Phase 3 clinical study of
IKT-001 in PAH, including the timing, design, initiation and conduct of the
IMPROVE-PAH study and related regulatory submissions, the Company’s ability to obtain additional regulatory approvals for the
IMPROVE-PAH study, the Company’s beliefs regarding the potential advantages of the Phase 3 clinical study of
IKT-001, the potential benefits of Orphan Drug Designation, the Company’s expectations regarding its cash runway and ability to fund operations through topline data readout in Part B of
IMPROVE-PAH, or future events or conditions. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate
IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form
10-K and Form
10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.³
Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors mmoyer@lifesciadvisors.com
---tables to follow---⁴
Inhibikase Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)⁵
Inhibikase Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
Inhibikase Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)